Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Research analysts at Seaport Res Ptn issued their Q1 2026 earnings estimates for Curaleaf in a report released on Wednesday, March 5th. Seaport Res Ptn analyst S. Randhawa forecasts that the company will earn ($0.06) per share for the quarter. The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.19) EPS.
Separately, Roth Capital upgraded shares of Curaleaf to a “strong-buy” rating in a research report on Sunday, November 10th.
Curaleaf Stock Performance
CURLF opened at $1.01 on Friday. The firm’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $2.14. The company has a market cap of $667.23 million, a price-to-earnings ratio of -3.48 and a beta of 0.57. The company has a quick ratio of 0.51, a current ratio of 1.11 and a debt-to-equity ratio of 0.85. Curaleaf has a 52-week low of $0.88 and a 52-week high of $6.40.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09. The business had revenue of $331.05 million for the quarter, compared to the consensus estimate of $331.87 million. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
- Five stocks we like better than Curaleaf
- Golden Cross Stocks: Pattern, Examples and Charts
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks to Buy While Others Stay on the Sidelines
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
